Other Current Assets

6 Months Ended

Jun. 30, 2018

Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]

Other Current Assets

4. Other Current Assets

As of June 30, 2018, Other Current Assets included prepaid expenses of $0.6 million, comprised primarily of prepayments made to the Company’s clinical research organization for our clinical trial for prexigebersen in CML of $0.4 million and prepaid insurance of $0.2 million. As of December 31, 2017, Other Current Assets included prepaid expenses of $0.4 million.